SI2299987T1 - Kapsulna farmacevtska odmerna oblika, obsegajoča suspenzijsko formulacijo indolinonskega derivata - Google Patents
Kapsulna farmacevtska odmerna oblika, obsegajoča suspenzijsko formulacijo indolinonskega derivata Download PDFInfo
- Publication number
- SI2299987T1 SI2299987T1 SI200931833T SI200931833T SI2299987T1 SI 2299987 T1 SI2299987 T1 SI 2299987T1 SI 200931833 T SI200931833 T SI 200931833T SI 200931833 T SI200931833 T SI 200931833T SI 2299987 T1 SI2299987 T1 SI 2299987T1
- Authority
- SI
- Slovenia
- Prior art keywords
- capsule
- formulation
- active substance
- suspension formulation
- weight
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title claims abstract 19
- 238000009472 formulation Methods 0.000 title claims abstract 12
- 239000000203 mixture Substances 0.000 title claims abstract 12
- 239000000725 suspension Substances 0.000 title claims abstract 8
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title claims 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 claims abstract 4
- MMMVNAGRWOJNMW-FJBFXRHMSA-N nintedanib esylate Chemical compound CCS(O)(=O)=O.O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 MMMVNAGRWOJNMW-FJBFXRHMSA-N 0.000 claims abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 239000007963 capsule composition Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 229940057917 medium chain triglycerides Drugs 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000001828 Gelatine Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000000771 oncological effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000005022 packaging material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (9)
- Kapsulna farmacevtska odmema oblika, obsegajoča suspenzijsko formulacijo indolinonskega derivata Patentni zahtevki1. Formulacija aktivne snovi 3-Z-[l-(4-(N-((4-metil-piperazin-l-il)-metil-karbonil)-N-metil-amino)-anilino)-l-fenil-metilen]-6-rnetoksikarbonil-2-indolinon-monoetansulfonat, ki obsega viskozno lipidno suspenzijo aktivne snovi v 1-90 mas. % srednjeverižnih trigliceridov, 1-30 mas. % trdne maščobe in 0,1-10 mas. % lecitina.
- 2. Formulacija po zahtevku 1, ki obsega lipidno suspenzijo aktivne snovi v 10-70 mas. % srednjeverižnih trigliceridov, 10-30 mas. % trdne maščobe in 0,25-2,5 mas. % lecitina.
- 3. Kapsula, ki obsega kapsulno ovojnico in kapsulno formulacijo, označena s tem, da kapsulna formulacija obsega formulacijo po zahtevku 1 ali 2.
- 4. Kapsula po zahtevku 3, označena s tem, daje kapsula mehka želatinska kapsula.
- 5. Kapsula po zahtevku 3, označena s tem, da kapsulna ovojnica obsega glicerol kot mehčalo.
- 6. Kapsula po zahtevku 3, označena s tem, da je kapsula trda želatinska ali hidroksipropilmetilcelulozna (HPMC) kapsula, kapsula iz polivinilalkoholnega polimera ali kapsula iz pululana, po izbiri z zatesnitvijo ali ovitjem (banding).
- 7. Formulacija po zahtevku 1 ali 2 ali kapsula po zahtevkih 3-6 za uporabo kot zdravilo.
- 8. Formulacija po zahtevku 1 ali 2 ali kapsula po zahtevkih 3-6 za uporabo kot farmacevtski sestavek z antiproliferativno aktivnostjo.
- 9. Formulacija po zahtevku 1 ali 2 ali kapsula po zahtevkih 3-6 za uporabo pri zdravljenju bolezni ali stanja, izbranega izmed onkoloških bolezni, imunoloških bolezni ali patoloških stanj, ki vključujejo imunološko komponento, in fibrotičnih bolezni.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08157748 | 2008-06-06 | ||
| EP09757593.0A EP2299987B1 (en) | 2008-06-06 | 2009-06-04 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| PCT/EP2009/056878 WO2009147212A1 (en) | 2008-06-06 | 2009-06-04 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2299987T1 true SI2299987T1 (sl) | 2018-06-29 |
Family
ID=40911908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200931833T SI2299987T1 (sl) | 2008-06-06 | 2009-06-04 | Kapsulna farmacevtska odmerna oblika, obsegajoča suspenzijsko formulacijo indolinonskega derivata |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20110301177A1 (sl) |
| EP (1) | EP2299987B1 (sl) |
| JP (2) | JP5661031B2 (sl) |
| KR (2) | KR101725469B1 (sl) |
| CN (2) | CN102056598B (sl) |
| AR (1) | AR072059A1 (sl) |
| AU (1) | AU2009254548B2 (sl) |
| BR (1) | BRPI0913434B8 (sl) |
| CA (1) | CA2726267C (sl) |
| CL (1) | CL2010001279A1 (sl) |
| CO (1) | CO6280467A2 (sl) |
| CY (1) | CY1120533T1 (sl) |
| DK (1) | DK2299987T3 (sl) |
| EA (1) | EA029996B1 (sl) |
| EC (1) | ECSP10010660A (sl) |
| ES (1) | ES2669469T3 (sl) |
| HR (1) | HRP20180709T1 (sl) |
| HU (1) | HUE039187T2 (sl) |
| IL (1) | IL208954A (sl) |
| LT (1) | LT2299987T (sl) |
| MA (1) | MA32385B1 (sl) |
| MX (2) | MX2010013203A (sl) |
| MY (1) | MY158930A (sl) |
| NO (1) | NO2299987T3 (sl) |
| NZ (1) | NZ603162A (sl) |
| PE (1) | PE20100254A1 (sl) |
| PL (1) | PL2299987T3 (sl) |
| PT (1) | PT2299987T (sl) |
| RS (1) | RS57142B1 (sl) |
| SI (1) | SI2299987T1 (sl) |
| TW (1) | TW201002691A (sl) |
| UA (1) | UA104590C2 (sl) |
| UY (1) | UY31879A (sl) |
| WO (1) | WO2009147212A1 (sl) |
| ZA (1) | ZA201007636B (sl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| DK2299987T3 (en) | 2008-06-06 | 2018-05-22 | Boehringer Ingelheim Int | Pharmaceutical Capsule Dosage Form Containing A Suspension Formulation Of An Indolinone Derivative |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| JO3587B1 (ar) * | 2010-06-02 | 2020-07-05 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| GB201020032D0 (en) * | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| CA2883807A1 (en) | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents |
| US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
| CA3172586A1 (en) | 2013-07-31 | 2015-02-05 | Avalyn Pharma Inc. | Aerosol imatininb compounds and uses thereof |
| US20150209360A1 (en) * | 2014-01-30 | 2015-07-30 | Orbz, Llc | Oral caffeine delivery composition |
| CN112156081A (zh) * | 2015-03-13 | 2021-01-01 | 江苏豪森药业集团有限公司 | 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法 |
| CN107019697A (zh) * | 2016-02-02 | 2017-08-08 | 瑞阳(苏州)生物科技有限公司 | 预防或治疗纤维化疾病的药物组合物及其应用 |
| US10561630B2 (en) * | 2016-10-25 | 2020-02-18 | Glykon Technologies Group, Llc | Hydroxycitric acid compounds and capsule liquid delivery |
| CN108066343A (zh) * | 2016-11-08 | 2018-05-25 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗肾纤维化疾病的药物 |
| CN110062625A (zh) | 2016-12-12 | 2019-07-26 | 勃林格殷格翰国际有限公司 | 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法 |
| WO2018177893A1 (en) | 2017-03-28 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of muscular dystrophy |
| CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
| EA202090977A1 (ru) | 2017-10-23 | 2020-09-04 | Бёрингер Ингельхайм Интернациональ Гмбх | Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild) |
| WO2019106692A1 (en) * | 2017-11-29 | 2019-06-06 | Sun Pharmaceutical Industries Limited | Oral suspension of nintedanib esylate |
| CA3093225A1 (en) | 2018-03-07 | 2019-09-12 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| CN113292537B (zh) | 2018-06-15 | 2024-04-05 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| US20230158018A1 (en) * | 2018-09-13 | 2023-05-25 | Ftf Pharma Private Limited | Non-aqueous chemotherapeutic suspensions for oral dosage |
| CA3116298A1 (en) * | 2018-10-15 | 2020-04-23 | Cipla Limited | Pharmaceutical formulation |
| CN112386580B (zh) * | 2019-08-13 | 2022-07-08 | 齐鲁制药有限公司 | 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用 |
| US20230000846A1 (en) | 2019-12-04 | 2023-01-05 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| US20230135671A1 (en) | 2020-04-01 | 2023-05-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
| EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
| CN114404382B (zh) * | 2022-01-24 | 2023-05-12 | 南京康川济医药科技有限公司 | 乙磺酸尼达尼布软胶囊及其制备方法 |
| WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
| WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870062A (en) | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| DE3579384D1 (de) | 1984-07-24 | 1990-10-04 | Scherer Gmbh R P | Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung. |
| GB9313329D0 (en) * | 1993-06-28 | 1993-08-11 | Scherer Ltd R P | Softgel capsule shell compositions |
| DE19603402A1 (de) | 1995-02-24 | 1996-08-29 | Basf Ag | Weichgelatinekapseln |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| AU2002236166B2 (en) * | 2001-05-01 | 2006-12-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition |
| DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US20060293260A1 (en) * | 2005-05-24 | 2006-12-28 | Wyeth | Useful high load concentrate compositions for control of ecto-and endo-parasites |
| DK1948180T3 (da) * | 2005-11-11 | 2013-05-27 | Boehringer Ingelheim Int | Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer |
| UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
| EP2293795B1 (en) | 2008-06-06 | 2015-08-12 | Boehringer Ingelheim International GmbH | Pharmaceutical combination |
| DK2299987T3 (en) | 2008-06-06 | 2018-05-22 | Boehringer Ingelheim Int | Pharmaceutical Capsule Dosage Form Containing A Suspension Formulation Of An Indolinone Derivative |
| EP2387401A1 (en) * | 2009-01-14 | 2011-11-23 | Boehringer Ingelheim International GmbH | Method for treating colorectal cancer |
| US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
| JP2012526766A (ja) | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腫瘍性及び線維性疾患の処置における新規な併用療法 |
-
2009
- 2009-06-04 DK DK09757593.0T patent/DK2299987T3/en active
- 2009-06-04 CN CN200980121067.8A patent/CN102056598B/zh not_active Ceased
- 2009-06-04 LT LTEP09757593.0T patent/LT2299987T/lt unknown
- 2009-06-04 NZ NZ60316209A patent/NZ603162A/en unknown
- 2009-06-04 MY MYPI2010005645A patent/MY158930A/en unknown
- 2009-06-04 BR BRPI0913434A patent/BRPI0913434B8/pt active IP Right Grant
- 2009-06-04 EA EA201001856A patent/EA029996B1/ru not_active IP Right Cessation
- 2009-06-04 US US12/995,869 patent/US20110301177A1/en not_active Abandoned
- 2009-06-04 CA CA2726267A patent/CA2726267C/en active Active
- 2009-06-04 KR KR1020107027317A patent/KR101725469B1/ko active IP Right Grant
- 2009-06-04 SI SI200931833T patent/SI2299987T1/sl unknown
- 2009-06-04 NO NO09757593A patent/NO2299987T3/no unknown
- 2009-06-04 AU AU2009254548A patent/AU2009254548B2/en active Active
- 2009-06-04 PE PE2009000782A patent/PE20100254A1/es not_active Application Discontinuation
- 2009-06-04 MX MX2010013203A patent/MX2010013203A/es active IP Right Grant
- 2009-06-04 MX MX2014006908A patent/MX359229B/es unknown
- 2009-06-04 ES ES09757593.0T patent/ES2669469T3/es active Active
- 2009-06-04 PL PL09757593T patent/PL2299987T3/pl unknown
- 2009-06-04 KR KR1020177004310A patent/KR20170020557A/ko not_active Application Discontinuation
- 2009-06-04 UA UAA201100098A patent/UA104590C2/ru unknown
- 2009-06-04 JP JP2011512128A patent/JP5661031B2/ja active Active
- 2009-06-04 PT PT97575930T patent/PT2299987T/pt unknown
- 2009-06-04 WO PCT/EP2009/056878 patent/WO2009147212A1/en active Application Filing
- 2009-06-04 RS RS20180491A patent/RS57142B1/sr unknown
- 2009-06-04 EP EP09757593.0A patent/EP2299987B1/en active Active
- 2009-06-04 CN CN201510660732.8A patent/CN105193720B/zh not_active Ceased
- 2009-06-04 HU HUE09757593A patent/HUE039187T2/hu unknown
- 2009-06-05 TW TW098118825A patent/TW201002691A/zh unknown
- 2009-06-05 AR ARP090102039A patent/AR072059A1/es unknown
- 2009-06-08 UY UY0001031879A patent/UY31879A/es not_active Application Discontinuation
-
2010
- 2010-10-26 ZA ZA2010/07636A patent/ZA201007636B/en unknown
- 2010-10-26 IL IL208954A patent/IL208954A/en active IP Right Grant
- 2010-11-22 CL CL2010001279A patent/CL2010001279A1/es unknown
- 2010-12-03 EC EC2010010660A patent/ECSP10010660A/es unknown
- 2010-12-03 CO CO10152519A patent/CO6280467A2/es not_active Application Discontinuation
- 2010-12-06 MA MA33402A patent/MA32385B1/fr unknown
-
2013
- 2013-08-30 US US14/015,186 patent/US20140004187A1/en not_active Abandoned
-
2014
- 2014-08-11 JP JP2014163667A patent/JP5905542B2/ja active Active
-
2015
- 2015-10-07 US US14/877,132 patent/US20160022672A1/en not_active Abandoned
-
2016
- 2016-07-07 US US15/204,277 patent/US9907756B2/en active Active
-
2018
- 2018-05-07 HR HRP20180709TT patent/HRP20180709T1/hr unknown
- 2018-05-15 CY CY20181100499T patent/CY1120533T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2299987T1 (sl) | Kapsulna farmacevtska odmerna oblika, obsegajoča suspenzijsko formulacijo indolinonskega derivata | |
| AU2006332677B2 (en) | Methods for treating cutaneous lupus using aminoisoindoline compounds | |
| CN110337290A (zh) | 舌下右旋美托咪啶用于治疗激越的用途 | |
| FI2313087T4 (fi) | Farmaseuttinen annostelumuoto indolinoni-johdannaisen välittömään vapautumiseen | |
| EA200702627A1 (ru) | Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования | |
| WO2011110939A2 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
| PT2246051E (pt) | Método de produção de comprimido de desintegração rápida por via oral que compreende imidafecina como princípio ativo | |
| JP5749247B2 (ja) | 経口用徐放性固形製剤 | |
| CN1303280A (zh) | 氟西汀及其对映体的稳定剂型 | |
| RU2004132205A (ru) | Комбинации эпинастина, белладонны и псевдоэфедрина в качестве новых фармацевтических составов | |
| AU2014234258B2 (en) | Piperaquine microcapsules and compositions containing them | |
| UA94251C2 (ru) | Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение | |
| AU2015227503B2 (en) | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative | |
| JP2024507367A (ja) | ムスカリン受容体活性化によって改善される障害を処置するための方法 | |
| EA201070175A1 (ru) | Фармацевтическая композиция контролируемого высвобождения, содержащая толперизона гидрохлорид | |
| KR101125087B1 (ko) | 약물 포장체 | |
| Kumar | Design/Development and Evaluation of Buccal Patches of an Antihypertensive Drug | |
| Reddy | Formulation and Evaluation of Transdermal Patches of Metoprolol Tartrate Using Conjugated Polymers | |
| TN2010000558A1 (en) | Capsule pharmaceutical doage form comprising a suspension formulation of an indolinone derivative | |
| JP2007015950A (ja) | 被覆した制酸剤 |